Menu Search
Equities

Genmab A/S

GNMSF:PKC

Genmab A/S

Actions
  • Price (USD)208.00
  • Today's Change5.52 / 2.73%
  • Shares traded77.37k
  • 1 Year change-32.40%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:54 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in DKK

The one analyst offering a 12 month price target expects Genmab A/S share price to rise to 395.78 in the next year from the last price of 208.00.
High90.3%395.78
Med90.3%395.78
Low90.3%395.78

Earnings history & estimates in DKK

On Nov 06, 2024, Genmab A/S reported 3rd quarter 2024 earnings of 19.81 per share.
The next earnings announcement is expected on Feb 12, 2025.
Average growth rate+9.36%
Genmab A/S reported annual 2023 earnings of 66.02 per share on Feb 14, 2024.
Average growth rate+34.47%
More ▼

Revenue history & estimates in DKK

-32768 had 3rd quarter 2024 revenues of 5.54bn. This missed the 5.69bn consensus estimate of the 9 analysts following the company. This was 94.11% above the prior year's 3rd quarter results.
Average growth rate+5.03%
-32768 had revenues for the full year 2023 of 16.47bn. This was 12.87% above the prior year's results.
Average growth rate+39.32%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.